Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
NCT00629499Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2008
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in breast cancer, sponsored by SCRI Development Innovations. Primary endpoint: Number of Participants Who Remained Alive Without Evidence of Recurrence as a Measure of Tolerability of Adjuvant Nab Paclitaxel at 18 months. Started Apr 2008; status: completed.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00629499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00629499.